A Phase 1 interventional study of 5-fluorouracil and cisplatin in Stomach Neoplasms, sponsored by Pfizer. Completed at 3 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-12-19.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 78 studies testing fluorouracil in Stomach Neoplasms — 6 open to participants now, 8 under way, 1 of them phase 3. Fluorouracil · Stomach Neoplasms.
Among the 78 studies testing fluorouracil in Stomach Neoplasms, this one is the 49th largest by enrollment of the 73 interventional ones that give a count, is one of 5 that started in 2008, is one of 14 in phase 1, and was the 34th registered.
3,401 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →6 of the 78 studies testing fluorouracil in Stomach Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Canada, China and 8 more countries
Ages 18+
Fudan University · Sites in China
Ages 18+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18+
By country, each count listing its studies:
Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
78 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 53 · Phase 3 8 · Phase 4 2
First in 1996; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 34 is below the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 50 across the 73 interventional studies. Of the 59 that completed or were terminated, 18 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 78 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
27 studies in Stomach Neoplasms by Pfizer: 5 open now, 7 under way, 1 of them phase 3. Of 20 finished, 10 (50%) have results posted.
Among the 27 studies in Stomach Neoplasms by Pfizer, this one is the 20th largest by enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2008, is one of 18 in phase 1, and was the 6th registered.
Pfizer’s Stomach Neoplasms studies by the year they started, since 2002.
3 of the studies testing fluorouracil in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07085273The First Affiliated Hospital of Zhengzhou UniversityIrinotecan Liposome II + 5-FU/LV + Oxaliplatin + Karelizumab in Neoadjuvant Treatment of Gastric Cancer | 2026-12-31 |
| NCT07257575Guangdong Provincial People's HospitalA Randomized Controlled Study of Serplulimab Combined With Chemotherapy for Locally Advanced Gastric Adenocarcinoma | 2027-01-31 |
| NCT07069712AstraZenecaA Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma | 2027-11-09 |
Add all 3 to your calendar (.ics) → With an account.
Among the 78 studies testing fluorouracil in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 27 in Stomach Neoplasms:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safe and tolerable dose of sunitinib when given together with cisplatin and 5-fluorouracil in patients with advanced gastric cancer who have not received prior chemotherapy for their advanced cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: 5-fluorouracil · Drug: cisplatin · Drug: sunitinib malate
5- fluorouracil is given as 4000 mg/m\^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Cisplatin is given 80 mg/m\^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
Number of Participants With First-cycle Dose Limiting Toxicities (DLTs)
The incidence of DLTs assessed during the first cycle (21 days).
Time frame: Cycle 1 (Baseline to Day 21)
Maximum Observed Plasma Concentration (Cmax)
Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)
Area Under the Curve From Time 0 to 24 Hours Postdose [AUC (0-24)]
Area under the plasma concentration versus time curve from time 0 (pre-dose) to 24 hours postdose (0-24).
Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours postdose)
Time to Reach Maximum Observed Plasma Concentration (Tmax)
Tmax is the time to first occurrence of maximum observed plasma concentration (Cmax).
Time frame: Day 1 of Cycle 1 (2, 4, 6, 8, 10, and 24 hours post dose)
Steady State Concentration (Css) of 5-Fluorouracil (5-FU)
Steady state plasma concentration of 5-FU equals AUC(2-6) divided by 4, where AUC(2-6) is the area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).
Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Infusion Rate (Zero Order) (R0) of 5-FU
Infusion rate of 5-FU equals total dose divided by infusion time.
Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Clearance (CLss) of 5-FU
Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of 5-FU (R0/Css).
Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU
Area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).
Time frame: Day 1 of Cycle 1 (2, 4, and 6 hours post infusion)
Number of Participants With Objective Response
Number of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
Time frame: Baseline, Day 21 of every even-numbered cycle up to 15 Months
Duration of Response (DR)
Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to any cause, whichever occurrs first. DR calculated as (Months) equals (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 30.
Time frame: Baseline up to Month 15
Progression-Free Survival (PFS)
Median time (50%) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Months) equals (first event date minus first dose date plus 1) divided by 30.
Time frame: Baseline up to Month 15
| Milestone | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Started | 24 | 10 |
| Completed | 0 | 0 |
| Not completed | 24 | 10 |
| Withdrew: Death | 0 | 2 |
| Withdrew: Adverse event | 8 | 2 |
| Withdrew: Objective progression or relapse | 11 | 5 |
| Withdrew: Other | 3 | 1 |
| Withdrew: Participant refused | 2 | 0 |
The incidence of DLTs assessed during the first cycle (21 days).
| Participants | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Number of Participants With First-cycle Dose Limiting Toxicities (DLTs) | 1 | 0 |
| nanograms per milliliter (ng/mL) | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Sunitinib | 16.8 ± 8.19 |
| SU012662 (metabolite of Sunitinib) | 2.24 ± 1.29 |
| Total Drug (Sunitinib + SU012662) | 19.0 ± 9.35 |
Area under the plasma concentration versus time curve from time 0 (pre-dose) to 24 hours postdose (0-24).
| ng*h/mL | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Sunitinib | 249 ± 127 |
| SU012662 (metabolite of Sunitinib) | 34.0 ± 19.5 |
| Total Drug (Sunitinib + SU012662) | 283 ± 144 |
Tmax is the time to first occurrence of maximum observed plasma concentration (Cmax).
| hours | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Sunitinib | 4.00 (2.00 to 24.0) |
| SU012662 (metabolite of Sunitinib) | 4.00 (2.00 to 24.0) |
| Total Drug (Sunitinib + SU012662) | 4.00 (2.00 to 24.0) |
Steady state plasma concentration of 5-FU equals AUC(2-6) divided by 4, where AUC(2-6) is the area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).
| ng/mL | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Steady State Concentration (Css) of 5-Fluorouracil (5-FU) | 593 ± 433 |
Infusion rate of 5-FU equals total dose divided by infusion time.
| mg/hr | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Infusion Rate (Zero Order) (R0) of 5-FU | 68.2 ± 12.5 |
Steady state total body clearance equals infusion rate (zero order) divided by steady state plasma concentration of 5-FU (R0/Css).
| Liters per hour | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Clearance (CLss) of 5-FU | 161 ± 93.2 |
Area under the plasma concentration versus time curve from time 2 to 6 hours postdose (2-6).
| ng*h/mL | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU |
|---|---|
| Area Under the Curve From Time 2 to 6 Hours Postdose [AUC (2-6)] of 5-FU | 2372 ± 1729 |
Number of participants with an objective response-based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as the disappearance of all target lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.
| Participants | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Number of Participants With Objective Response | 6 | 3 |
Time from the first objective documentation of tumor response (confirmed or partial response) to first documented objective tumor progression or death due to any cause, whichever occurrs first. DR calculated as (Months) equals (the end date for DR minus first subsequent confirmed CR or PR plus 1) divided by 30.
| Months | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Duration of Response (DR) | 4.17 ± 2.28 | 4.13 ± 0.73 |
Median time (50%) from the first dose of study treatment to the first documentation of objective tumor progression or to death due to any cause, whichever occurs first. PFS calculated as (Months) equals (first event date minus first dose date plus 1) divided by 30.
| Months | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Progression-Free Survival (PFS) | 5.2 (3.8 to 7.6) | 6.2 (3.3 to 6.9) |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | — | 7/24 (29.2%) | 24/24 (100%) |
| Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU | — | 5/10 (50%) | 10/10 (100%) |
| Event | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| Mucosal inflammationGeneral disorders | 0/24 | 3/10 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/24 | 2/10 |
| AnaemiaBlood and lymphatic system disorders | 0/24 | 1/10 |
| DiarrhoeaGastrointestinal disorders | 0/24 | 1/10 |
| OesophagitisGastrointestinal disorders | 0/24 | 1/10 |
| VomitingGastrointestinal disorders | 0/24 | 1/10 |
| Device occlusionGeneral disorders | 0/24 | 1/10 |
| Disease progressionGeneral disorders | 0/24 | 1/10 |
| FatigueGeneral disorders | 0/24 | 1/10 |
| RashSkin and subcutaneous tissue disorders | 0/24 | 1/10 |
| Event | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 21/24 | 10/10 |
| VomitingGastrointestinal disorders | 13/24 | 9/10 |
| Mucosal inflammationGeneral disorders | 19/24 | 8/10 |
| AstheniaGeneral disorders | 19/24 | 7/10 |
| Decreased appetiteMetabolism and nutrition disorders | 12/24 | 7/10 |
| AnaemiaBlood and lymphatic system disorders | 12/24 | 6/10 |
| NauseaGastrointestinal disorders | 14/24 | 4/10 |
| ThrombocytopeniaBlood and lymphatic system disorders | 6/24 | 5/10 |
| FatigueGeneral disorders | 1/24 | 5/10 |
| Abdominal pain upperGastrointestinal disorders | 6/24 | 4/10 |
| Age Continuous(years) | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU | Total |
|---|---|---|---|
| Mean | 60.1 ± 12.0 | 56.4 ± 10.4 | 59.0 ± 11.5 |
| Sex: Female, Male(Participants) | Sunitinib (25 mg) in Combination With Cisplatin and 5-FU | Sunitinib (37.5 mg) in Combination With Cisplatin and 5-FU | Total |
|---|---|---|---|
| Female | 7 | 4 | 11 |
| Male | 17 | 6 | 23 |
The record gives a start of Aug 2008, a primary completion of Dec 2009 and a completion of Aug 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2011, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluorouracil · Cisplatin · Sunitinib